Potential Herb-Drug Interactions for Commonly Used Herbs*

Drug
Warfarin Potentiation of bleeding possible at very high bilberry doses. May decrease effectiveness of drug due to natural iodine content.2 May add to effect of drug. Theoretical concern linked to a case report where kelp caused hyperthyroidism in a person not taking thyroxin.3 Case report. Contraindicated. Contraindicated. Monitor (very low level of risk). Monitor (low level of risk). Monitor (very low level of risk). Monitor (low level of risk). Antiplatelet activity observed for high doses of bilberry in human volunteers.1 Theoretical concern, no cases reported.

Herb

Potential Interaction

Basis of Concern

Recommended Action
Monitor at high doses (> 100 mg/day anthocyanins, low level of risk). Contraindicated unless under close supervision. Monitor (low level of risk).

Bilberry Vaccinium myrtillus Bladderwrack Fucus vesiculosus Hyperthyroid medication eg carbimazole Thyroid replacement therapies eg thyroxine Radioactive iodine Thyroid hormones ACE inhibitor Theophylline Increased absorption and bioavailability.7 Reduced serum levels of thyroxine.8 May potentiate effects of drug. Case reports. Thyroxine Antiplatelet medication Hypotensive medication May potentiate effects of drug. May potentiate effects of drug. Prescribed medication Warfarin Warfarin Warfarin Immunosuppressant medication Digoxin May interfere with administration of diagnostic procedures using radioactive isotopes.4 Should not be administered concurrently with preparations containing thyroid hormone.5 Cough induced by topical capsaicin.6

Bugleweed Lycopus virginicus Lycopus europaeus

Cayenne (Chilli Pepper) Capsicum spp.

Theoretical concern based on deliberations of German Commission E. Theoretical concern since capsaicin depletes substance P. Clinical study.

Celery Seed Apium graveolens Coleus Coleus forskohlii

HERB-DRUG INTERACTION CHART

www.mediherb.com

Monitor (low level of risk). Monitor (low level of risk). Contraindicated. One case report with very few details. Unlikely to occur. Case reports. Monitor (very low level of risk). Monitor (low level of risk).

May potentiate effect of drug: increased INR,12-14 prolonged APTT. Purpura15 possibly due to increased bleeding tendency. May potentiate effect of drug: increased INR and PT;16 increased INR and widespread bruising.17 May decrease effectiveness of drug.18,19

Theoretical concern based on in vivo animal studies of standardized coleus extract and the active constituent forskolin.9 Theoretical concern based on ability of forskolin to lower blood pressure in vivo.10 Theoretical concern based on ability of forskolin to activate increased intracellular cyclic AMP in vitro.11 Case reports.

Theoretical concern based on immune-enhancing activity of Echinacea. No adverse events reported. Apparently raised serum concentrations.20

Dan Shen Salvia miltiorrhiza Devils Claw Harpagophytum procumbens Dong Quai Angelica sinensis Angelica polymorpha Echinacea Echinacea angustifolia Echinacea purpurea Eleuthero Eleutherococcus senticosus Phenothiazines

Contraindicated.

Evening Primrose Oil Oenothera biennis

May decrease effectiveness of drug.

Herb probably interfered with digoxin assay (patient Monitor (very low level of risk). had unchanged ECG despite apparent digoxin concentration of 5.2 nmol/L). Reports of worsening epilepsy in schizophrenics. Monitor (very low level of risk). No causal association demonstrated and no effect observed in later trials.21

131

HERB-DRUG INTERACTION CHART

Herb
Garlic Allium sativum Could increase bleeding time.22 Decreased serum levels of saquinavir.26 May potentiate effect of drug: increased INR observed.27 Large doses could increase bleeding tendency. May decrease effectiveness of drug. May increase effectiveness of drug: increased INR reported. Increased risk of spontaneous bleeding. HIV protease inhibitors eg saquinavir Warfarin Ginger Zingiber ofcinale Phenprocoumon Warfarin Antacids Aspirin

Drug

Potential Interaction

Basis of Concern
Case reports of increased bleeding tendency with high garlic intake.23-25 Clinical study. Case reports of possible interaction27 and increased bleeding tendency.23-25 Theoretical concern since ginger increases gastric secretory activity.18 One case reported (dosage undened).28

Recommended Action

Monitor at doses equivalent to > 5 g/day fresh garlic. Monitor (medium level of risk).

Contraindicated for doses equivalent to > 5 g/day fresh garlic unless under close supervision.

Monitor (low level of risk).

Monitor (low level of risk).

Ginkgo Ginkgo biloba Anticonvulsant medication eg sodium valproate, carbamazepine Antiplatelet and anticoagulant drugs eg aspirin, warfarin Haloperidol Hawthorn Crataegus monogyna Crataegus laevigata (Crataegus oxyacantha) Digoxin Hypoglycemic herbs eg Gymnema sylvestre, goats rue (Galega ofcinalis), fenugreek (Trigonella foenumgraecum) Hypoglycemic drugs and insulin Beta-blockers and other hypotensive drugs

May decrease the effectiveness of drug. Increased bleeding tendency. Ginkgo extract could have clinical antiplatelet activity.

May potentiate the efciency of haloperidol in patients with schizophrenia.38 May increase effectiveness of drug.

May increase effectiveness of drug.

Enhanced reduction of blood glucose.

Inhibits platelet aggregation and thromboxane after Monitor at doses < 4 g/day dried ginger. high doses (5 g/day) in volunteers. No effect at 2 g/day. Mechanism reportedly involves inhibition Contraindicated unless under close supervision at doses > 4 g/day dried ginger. of platelet cyclooxygenase.18 One case reported for warfarin (ginger dosage undened).29 No effect demonstrated in a clinical trial (3.6 g/day).30 Theoretical concern based on in vivo animal Monitor (medium level of risk). studies.31 Two case reports.32 Rare case reports of spontaneous bleeding, Aspirin: Monitor (low level of risk). including concomitant intake of aspirin or warfarin.33-35 Interactions with warfarin and aspirin Warfarin: Monitor (medium level of risk). are not supported by clinical studies.30,36,37 Randomized, controlled trial. Prescribe cautiously. Reduce drug if necessary in conjunction with prescribing physician. Clinical studies demonstrate hawthorn causes a Monitor (low level of risk). slight reduction in blood pressure in patients with heart conditions.18 Clinical studies indicate a (benecial) synergistic Monitor (low level of risk). effect.39,40 Pharmacokinetics not affected in a clinical study.41 Theoretical concern, no documented case histories.

www.mediherb.com

Prescribe cautiously and monitor blood sugar regularly. Warn patient about possible hypoglycemia. Reduce drug if necessary in conjunction with prescribing physician.

Herb
Antihypertensive medications May decrease effectiveness of drug. May potentiate effects of drug.18 May potentiate hypoglycemic activity of drug.19 Monitor (low level of risk). Monitor (very low level of risk). Monitor (very low level of risk). CNS stimulants Hypoglycemics

Drug

Potential Interaction

Basis of Concern

Recommended Action

Korean Ginseng Panax ginseng

MAO inhibitors eg phenelzine Headache and tremor, mania. Potentiation of drug possible. Sildenal Warfarin May decrease effectiveness of drug: decreased INR reported.47 May affect activity if potassium deciency resulting from long-term laxative abuse is present. May potentiate activity, if potassium deciency resulting from long-term laxative abuse is present. May increase potassium depletion.

Theoretical concern since hypertension is a feature of GAS. Clinical signicance unclear.18 Theoretical concern since CNS stimulation is a feature of GAS. Clinical signicance unclear. Theoretical concern based on clinically observed hypoglycemic activity of ginseng.42 Clinical signicance unclear. Case reports.43,44 Contraindicated. Monitor (very low level of risk). Monitor (low level of risk).

Laxative (anthraquinone-containing) herbs Antiarrhythmic agents eg aloe resin (Aloe barbadensis), senna (Cassia spp.), cascara (Rhamnus purshiana), yellow dock Cardiac glycosides (Rumex crispus) Potassium depleting agents eg thiazide diuretics, corticosteroids, licorice root (Glycyrrhiza glabra) Antihypertensive medications

Avoid excessive doses of laxatives. Maintain patients on a high potassium diet. Monitor (low level of risk at normal doses).

Licorice Glycyrrhiza glabra Cortisol Digoxin

Theoretical concern based on in vitro studies which show ginseng increases nitric oxide release from corpus cavernosum tissue.45,46 One case reported47 but clinical signicance unclear. No effect demonstrated in a clinical trial.48 German Commission E and ESCOP recommendation.5,49 German Commission E and ESCOP recommendation.5,49 German Commission E and ESCOP recommendation.5,49 Theoretical concern based on case reports of hypertension following intake of licorice-containing candy.18

Avoid excessive doses of laxatives. Maintain patients on a high potassium diet. Avoid long-term use at doses > 100 mg/day glycyrrhizin unless under close supervision. Place patients on a high potassium diet. Monitor (low level of risk).

HERB-DRUG INTERACTION CHART

www.mediherb.com

May decrease effectiveness of drug when consumed in high doses. Licorice can cause pseudoaldosteronism which includes edema and high blood pressure.18 Potentiation of drug possible by inhibition of drug metabolism. Excessive licorice intake causes hypokalemia which can potentiate the toxicity of the drug.5

Avoid long-term use at doses > 100 mg/day glycyrrhizin unless under close supervision. Place patients on a high potassium diet. Monitor (low level of risk). Avoid long-term use at doses > 100 mg/day glycyrrhizin. Place patients on a high potassium diet. Take at least 2 hours away from medication.

Prednisolone Thiazide diuretics and other potassium depleting drugs Prescribed medication Warfarin Metronidazole

Increases levels of drug by decreasing drug metabolism.18 The combined effect of licorice and the drug could result in excessive potassium loss.5 May slow or reduce absorption of drugs. May potentiate effects of drug. May decrease absorption of drug, by increasing clearance.54

Marshmallow Root Althaea ofcinalis Meadowsweet Filipendula ulmaria Milk Thistle Silybum marianum

Theoretical concern based on pharmacological studies and one early clinical study with the constituent (glycyrrhizin). No observed cases.18 Clinical studies of active constituents and case reports of hypokalemia from candy intake (large doses).18 One case report of ingestion of herbal laxative containing licorice (1.2 g/day) and rhubarb (4.8 g/day).50 Theoretical concern based on clinical studies of oral administration of active constituent glycyrrhizin.51,52 Clinical studies of active constituents and case reports from candy intake (large doses).18 Theoretical concern based on absorbent properties of marshmallow root. Theoretical concern based on in vivo animal studies demonstrating anticoagulant activity.53 Clinical study (silymarin: 140 mg/day).

Monitor (low level of risk). Contraindicated.

133

HERB-DRUG INTERACTION CHART

134

Herb

Potential Interaction

Basis of Concern

Recommended Action
In anemia and where iron supplementation is required, do not take simultaneously with meals or iron supplements.

Polyphenol - and avonoid-containing herbs. especially chamomile (Matricaria recutita), green tea (Camellia sinensis), lime owers (Tilia cordata), milk thistle (Silybum marianum), rosemary (Rosmarinus ofcinalis), vervain (Verbena ofcinalis)

(See also Tannin-containing herbs) Prescribed medication May accelerate clearance from the body. Prescribed medication May slow or reduce absorption of drugs. Decreases drug levels.67 May decrease drug levels via CYP induction.
68-70

Schisandra Schisandra chinensis

Monitor (medium level of risk). Take at least 2 hours away from medication. Monitor (medium level of risk). Monitor (low level of risk).

Slippery Elm Bark Ulmus rubra St Johns Wort Hypericum perforatum Amitriptyline Anticonvulsants eg phenytoin, carbamazepine, phenobarbitone Antihistamine eg fexofenadine Decreases drug levels.72 Decreases drug levels.73 Decreases drug levels.
74

Clinical studies (chamomile, green tea, lime owers, peppermint, rosemary, vervain, polyphenoliccontaining vegetable, red wine, coffee):55-59 (polyphenols per serving: approx. 30 mg56 and 50-200 mg55). Results for green tea have been conicting.56,60-62 An iron chelating activity for the avanolignan silybin is the suggested mechanism for the protection against iron-induced hepatic toxicity demonstrated in vivo (100 mg/kg).63,64 Theoretical concern based on in vivo studies demonstrating enhanced phase I/II hepatic metabolism.65,66 Theoretical concern based on absorbent properties of slippery elm. Clinical study. Theoretical concern. An open clinical trial demonstrated no effect on carbamazepine pharmacokinetics in healthy volunteers.71 Clinical study. Clinical study. Clinical study. Clinical studies.

Monitor (medium level of risk). Monitor (medium level of risk). Contraindicated. Contraindicated. Hyperforin-rich extracts: Monitor (medium level of risk). Low-hyperforin extracts: Monitor (low level of risk).

Benzodiazepines eg midazolam Calcium channel antagonists eg verapamil Cancer Chemotherapeutic drugs eg irinotecan, imatinib Combined oral contraceptives Decreases drug levels.75-77 Breakthrough bleeding reported which was attributed to increased metabolism of drug.78,79

www.mediherb.com

Digoxin

Decreases drug levels,85-87 but is dependent upon dose of herb,86 and the hyperforin content.88 Decreases drug levels.89 Decreases drug levels. Decreases drug levels.101 Decreases plasma drug levels.102 Decreases drug levels.103

Clinical signicance unclear. Cases of unwanted pregnancies have been reported.80,81 Contradictory results demonstrated in clinical studies.82 Preliminary results suggest extracts low in hyperforin may not affect plasma contraceptive drug levels.83,84 Clinical studies. Case report. Case reports,78,90-97 and case series.98,99 Interaction may be dependent upon the hyperforin content.100 Clinical study. Clinical study. Clinical study. Clinical signicance of case reports unclear. Case report.

HIV non-nucleoside transcriptase inhibitors eg nevirapine Immunosuppressives eg cyclosporin Other HIV protease inhibitors eg indinavir Phenprocoumon Simvastatin

Contraindicated at doses > 1 g/day dried herb, especially for high-hyperforin extracts. Contraindicated. Contraindicated especially for high-hyperforin extracts. Contraindicated. Contraindicated. Monitor (medium level of risk). Monitor (very low level of risk). Monitor (low level of risk).

SSRIs eg paroxetine, trazodone, sertraline and other Potentiation effects possible in regard to serotonin serotonergic agents eg nefazodone, venlafaxine levels.104-109 Theophylline Decreases drug levels.110 Warfarin Decreases drug levels and INR.48,79

Case reports and clinical study.

Contraindicated.

Herb
May reduce absorption of non-heme iron from food. Clinical studies (black tea 2.5 g/150 mL). Cases of iron deciency/reduced iron absorption: heavy black tea drinkers116,117 and those ingesting sorghum (0.15% tannins).118 In a clinical study tea consumption showed a small, non-signicant adverse effect on zinc bioavailability.119
55,111-115 111

Drug

Potential Interaction

Basis of Concern

Recommended Action
Take at least 2 hours away from medication.

Tannin- or OPC-containing herbs Minerals, especially iron eg grape seed extract (Vitis vinifera), green tea (Camellia sinensis), hawthorn (Crataegus spp.), meadowsweet (Filipendula ulmaria), raspberry leaf (Rubus idaeus), sage (Salvia ofcinalis), St Johns wort (Hypericum perforatum), uva ursi (Arctostaphylos uva-ursi), willow bark (Salix spp.) Antiplatelet or anticoagulant medications eg aspirin and warfarin May potentiate effects of drug. CNS depressants or alcohol May potentiate effects of drug. Warfarin May potentiate effects of drug.

(See also Polyphenol-containing herbs) Turmeric Curcuma longa

Valerian Valeriana ofcinalis

Monitor (low level of risk at normal doses). Contraindicated in high doses (> 15 g/day dried tuber). Monitor (very low level of risk). Monitor (low level of risk).

Willow Bark Salix alba Salix daphnoides Salix purpurea Salix fragilis

Theoretical concern based on in vitro and in vivo studies mainly of the active constituent curcumin demonstrating antiplatelet activity.18 Theoretical concern expressed by US Pharmacopeial Convention. However a clinical study indicated no potentiation with alcohol.120 Clinical study observed very mild but signicant antiplatelet activity.121

HERB-DRUG INTERACTION CHART

www.mediherb.com
48 49 21 Mills S, Bone K (eds). The Essential Guide to Herbal Safety. Churchill Livingstone, USA, 2005. 22 Muller J, Clauson K. Drug Benef Trends 1998; 10(5): 33-50 23 Rose KD, Croissant PD, Parliament CF et al. Neurosurgery 1990; 26(5): 880-882 24 Burnham BE. Plast Reconstr Surg 1995; 95(1): 213 25 German K, Kumar U, Blackford HN. Br J Urol 1995; 76: 518 26 Piscitelli SC, Burstein AH, Welden N et al. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 4-7, 2000. Abstract No. 734. 27 Sunter W. Pharm J 1991; 246: 722 28 Kruth P, Brosi E, Fux R et al. Ann Pharmacother 2004; 38(2): 257-260 29 Lesho EP, Saullo L, Udvari-Nagy S. Cleve Clin J Med 2004; 71(8): 651-656 30 Jiang X, Williams KM, Liauw WS et al. Br J Clin Pharmacol 2005; 59(4): 425-432 31 Manocha A, Pillai KK, Husain SZ. Indian J Pharmacol 1996; 28(2): 84-87 32 Korth RM. MMW Fortschr Med 2001; 143(44): 13 33 Rosenblatt M, Mindel J. New Engl J Med 1997; 336(15): 1108 34 Fessenden JM, Wittenborn W, Clarke L. Am Surg 2001; 67(1): 33-35 35 Matthews MK Jr. Neurology 1998; 50(6): 1933-1934 36 Engelsen J, Nielsen JD, Winther K. Thromb Haemost 2002; 87(6): 1075-1076 37 DeLoughery TG, Kaye JA, Morris CD et al. Blood 2002; 11: Abstract #3809. 38 Zhang XY, Zhou DF, Su JM et al. J Clin Psychopharmacol 2001; 21(1): 85-88 39 Wolkerstorfer H. MMW 1966; 108: 438-441 40 Jaursch U, Landers E, Schmidt R et al. Med Welt 1969; 27: 1547-1552 41 Tankanow R, Tamer HR, Streetman DS et al. J Clin Pharmacol 2003; 43(6): 637-642 42 Sotaniemi EA, Haapakoski E, Rautio A. Diabetes Care 1995; 18(10): 1373-1375 43 Jones BD, Runikis AM. J Clin Psychopharmacol 1987; 7(3): 201-202 44 Shader RI, Greenblatt DJ. J Clin Psychopharmacol 1988; 8(4): 235 45 Gillis CN. Biochem Pharmacol 1997; 54(1): 1-8 46 Kim HJ, Woo DS, Lee G et al. Br J Urol 1998; 82(5): 744-748 47 Janetzky K, Morreale AP. Am J Health Syst Pharm 1997; 54: 692-693

(See also Tannin-containing herbs) CODE Contraindicated: Do not prescribe the indicated herb. Monitor: Can prescribe the indicated herb but maintain close contact and review the patients status on a regular basis. Note that where the risk is assessed as medium, self-prescription of the herb in conjunction with the drug is not advisable.

* Note: This chart contains information the authors believe to be reliable or which have received considerable attention as potential issues. However, many theoretical concerns expressed by other authors have not been included. # The word tannin has a long established and extensive usage although it is considered in more recent years to lack precision. Polyphenol is the preferred term when considering the properties at a molecular level. Plant polyphenols are broadly divisible into proanthocyanidins (condensed tannins) and polyesters based on gallic and/or hexahydroxydiphenic acid and their derivatives (hydrolyzable tannins).113 Heme iron is derived from hemoglobin and myoglobin mainly in meat products. Non-heme iron is derived mainly from cereals, vegetables and fruits. Plasma concentration of pravastatin not effected. Sorghum also contains phytate. Both phytate and polyphenol inhibit nutrients such as iron.122,123 Abbreviations: AMP: adenosine monophosphate; APTT: activated partial thromboplastin time; CNS: central nervous system; CYP: cytochrome P-450; ECG: electrocardiogram/graph; GAS: ginseng abuse syndrome; INR: international normalized ratio; PT: prothrombin time; SSRI: selective serotonin reuptake inhibitors; >: greater than; <: less than.
96 97

References:

General References: Braun L. Herb Drug Interaction Guide for Pharmacists. FH Faulding, August 2000; Fugh-Berman A. Lancet 2000; 355(9198): 134-138 Specic References: 1 Pulliero G, Montin S, Bettini V et al. Fitoterapia 1989; 60(1): 69-75 2 de Smet PAGM, Keller K, Hansel R et al (eds). Adverse Effects of Herbal Drugs, Volume 3. Springer-Verlag, Berlin, 1997. 3 Miller LG. Arch Intern Med 1998; 158: 2200-2211 4 de Smet PAGM, Keller K, Hansel R et al (eds). Adverse Effects of Herbal Drugs, Volume 2. Springer-Verlag, Berlin, 1993. 5 Blumenthal M et al (eds). The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, 1998. 6 Hakas JF. Ann Allergy 1990; 65: 322-323 7 Bouraoui A, Toum A, Bouchoucha S et al. Thrapie 1986; 41: 467-471 8 Moses G. Australian Prescriber 2001; 24(1): 6 9 de Souza NJ. J Ethnopharmacol 1993; 38(2-3): 177-180 10 de Souza NJ, Dohadwalla AN, Reden J. Med Res Rev 1983; 3(2): 201-219 11 Seamon KB, Daly JW. J Cyclic Nucleotide Res 1981; 7(4): 201-224 12 Tam LS, Chan TYK, Leung WK et al. Aust NZ J Med 1995; 25: 258 13 Yu CM, Chan JCN, Sanderson JE. J Intern Med 1997; 241: 337-339 14 Izzat MB, Yim APC, El-Zufari MH. Ann Thorac Surg 1998; 66: 941-942 15 Shaw D, Leon C, Kolev S et al. Drug Saf 1997; 17: 342-356 16 Page RL, Lawrence JD. Pharmacotherapy 1999; 19: 870-876 17 Ellis GR, Stephens MR. BMJ 1999; 319: 650 18 Mills S, Bone K. Principles and Practice of Phytotherapy: Modern Herbal Medicine. Churchill Livingstone, Edinburgh, 2000. 19 Newall CA, Anderson LA, Phillipson JD. Herbal Medicines - A Guide for Health-Care Professionals. Pharmaceutical Press, London, 1996. 20 McRae S. Can Med Assoc J 1996; 155: 293-295

70 Jiang X, Williams KM, Liauw WS et al. Br J Clin Pharmacol 2004; 57(5): 592-599 Henney JE. JAMA 2000; 283(13): 1679 71 Scientic Committee of ESCOP (European Scientic Cooperative on Phytotherapy). Burstein AH, Horton RL, Dunn T et al. Clin Pharmacol Ther 2000; 68(6): 605-612 72 ESCOP Monographs (Aloe capensis, Rhamni purshiani cortex, Sennae folium, Sennae Wang Z, Hamman MA, Huang SM et al. Clin Pharmacol Ther 2002; 71(6): 414-420 fructus acutifoliae, Sennae fructus angustifoliae). European Scientic Cooperative 73 Wang Z, Gorski JC, Hamman MA et al. Clin Pharmacol Ther 2001; 70(4): 317-326 on Phytotherapy, ESCOP Secretariat, Argyle House, Gandy Street, Exeter, Devon, EX4 74 Tannergren C, Engman H, Knutson L et al. Clin Pharmacol Ther 2004; 75(4): 298-309 3LS, UK. June 1997. 75 Mathijssen RH, Verweij J, de Bruijn P et al. J Natl Cancer Inst 2002; 94(16): 50 Harada T, Ohtaki E, Misu K et al. Cardiology 2002; 98(4): 218 1247-1249 51 Chen MF, Shimada F, Kato H et al. Endocrinol Jpn 1991; 38(2): 167-174 76 Mansky PJ, Straus SE. J Natl Cancer Inst 2002; 94(16): 1187-1188 52 Chen MF, Shimada F, Kato H et al. Endocrinol Jpn 1990; 37(3): 331-341 77 Smith PF, Bullock JM, Booker BM et al. Blood 2004; 104(4): 1229-1230 53 Liapina LA, Kovalchuk GA. Izv Akad Nauk Ser Biol 1993; (4): 625-628 78 Bon S, Hartmann K, Kuhn M. Schweiz Apoth 1999; 16: 535-536 54 Rajnarayana K, Reddy MS, Vidyasagar J et al. Arzneim Forsch 2004; 54(2): 109-113 79 Yue QY, Bergquist C, Gerden B. Lancet 2000; 355(9203): 576-577 55 Hurrell RF, Reddy M, Cook JD. Br J Nutr 1999; 81(4): 289-295 80 Information from the MPA (Medical Products Agency, Sweden) and the MCA 56 Samman S, Sandstrom B, Toft MB et al. Am J Clin Nutr 2001; 73(3): 607-612 (Medicines Control Agency, UK). 57 Tuntawiroon M, Sritongkul N, Brune M et al. Am J Clin Nutr 1991; 53(2): 554-557 81 Schwarz UI, Buschel B, Kirch W. Br J Clin Pharmacol 2003; 55(1): 112-113 58 Cook JD, Reddy MB, Hurrell RF. Am J Clin Nutr 1995; 61(4): 800-804 82 Schulz V. Phytomed 2006; 13(3): 199-204 59 Morck TA, Lynch SR, Cook JD. Am J Clin Nutr 1983; 37(3): 416-420 83 Will-Shahab L, Brattstrom A, Roots I et al. Symposium Phytopharmaka VII: 60 Prystai EA, Kies CV, Driskell JA. Nutr Res 1999; 19(2): 167-177 Forschung und klinische Anwendung, 12-13 October 2001, Berlin, pp 15-16. 61 Kubota K, Sakurai T, Nakazato K et al. Nippon Ronen Igakkai Zasshi 1990; 27(5): 84 Henderson L, Yue QY, Bergquist C et al. Br J Clin Pharmacol 2002; 54(4): 349-356 555-558 85 Johne A, Brockmoller J, Bauer S et al. Clin Pharmacol Ther 1999; 66(4): 338-345 62 Mitamura T, Kitazono M, Yoshimura O et al. Nippon Sanka Fujinka Gakkaai Zasshi 86 Uehleke B, Mueller SC, Uehleke B et al. Phytomed 2000; 7(Supp 2): 20 1989; 41(6): 688-694 87 Durr D, Stieger B, Kullak-Ublick GA et al. Clin Pharmacol Ther 2000; 68(6): 598-604 63 Pietrangelo A, Borella F, Casalgrandi G et al. Gastroenterology 1995; 109(6): 88 Mueller SC, Uehleke B, Woehling H et al. Clin Pharmacol Ther 2004; 75(6): 546-557 1941-1949 89 64 de Maat MMR, Hoetelmans RMW, Mathot RAA et al. AIDS 2001; 15(3): 420-421 Masini A, Ceccarelli D, Giovannini F et al. J Bioenerg Biomembr 2000; 32(2): 175-182 90 65 Ahmed SM, Banner NR, Dubrey SW. J Heart Lung Transplant 2001; 20(7): 795 Ko KM, Ip SP, Poon MK et al. Planta Med 1995; 61(2): 134-137 91 66 Ruschitzka F, Meier PJ, Turina M et al. Lancet 2000; 355(9203): 548-549 Lu H, Liu GT. Zhongguo Yao Li Xue Bao 1990; 11(4): 331-335 92 67 Mai I, Kruger H, Budde K et al. Int J Clin Pharmacol Ther 2000; 38(10): 500-502 Johne A, Schmider J, Brockmoller J et al. J Clin Psychopharmacol 2002; 22(1): 46-54 93 68 Karliova M, Treichel U, Malago M et al. J Hepatol 2000; 33(5): 853-855 Australian Therapeutic Goods Administration. Media Release, March 2000. 94 69 Rey JM, Walter G. Med J Aust 1998; 169(11-12): 583-586 Breckenridge A. Message from Committee on Safety of Medicines, 29 February 95 2000. Medicines Control Agency, London. Barone GW, Gurley BJ, Ketel BL et al. Transplantation 2001; 71(2): 239-241

98

Barone GW, Gurley BJ, Ketel BL et al. Ann Pharmacother 2000; 34(9): 1013-1016 Moschella C, Jaber BL. Am J Kidney Dis 2001; 38(5): 1105-1107 Beer AM, Ostermann T. Med Klin 2001; 96(8): 480-483 99 Breidenbach T, Kliem V, Burg M et al. Transplantation 2000; 69(10): 2229-2230 100 Mai I, Kruger H, Budde K et al. Int J Clin Pharmacol Ther 2000; 38(10): 500-502 101 Piscitelli SC, Burstein AH, Chaitt D et al. Lancet 2000; 355(9203): 547-548 102 Maurer A, Johne A, Bauer S et al. Eur J Clin Pharmacol 1999; 55: A22 103 Sugimoto K, Ohmori M, Tsuruoka S et al. Clin Pharmacol Ther 2001; 70(6): 518-524 104 Gordon JB. Am Fam Phys 1998; 57(5): 950, 953 105 Dermott K. Clinical Psychiatry News 1998; 26(3): 28 106 Barbenel DM, Yusuf B, OShea D et al. J Psychopharmacol 2000; 14(1): 84-86 107 Lantz MS, Buchalter E, Giambanco V. J Geriatr Psychiatry Neurol 1999; 12(1): 7-10 108 Prost N, Tichadou L, Rodor F et al. Presse Med 2000; 29(23): 1285-1286 109 Waksman JC, Heard K, Jolliff H et al. Clin Toxicol 2000; 38(5): 521 110 Nebel A, Schneider BJ, Baker RK et al. Ann Pharmacother 1999; 33: 502 111 Rossander L, Hallberg L, Bjorn-Rasmussen E. Am J Clin Nutr 1979; 32(12): 2484-2489 112 Disler PB, Lynch SR, Charlton RW et al. Gut 1975; 16(3): 193-200 113 Haslam E, Lilley TH. Crit Rev Food Sci Nutr 1988; 27(1): 1-40 114 Derman D, Sayers M, Lynch SR et al. Br J Nutr 1977; 38(2): 261-269 115 Merhav H, Amitai Y, Palti H et al. Am J Clin Nutr 1985; 41(6): 1210-1213 116 Zijp IM, Korver O, Tijburg LB. Crit Rev Food Sci Nutr 2000; 40(5): 371-98 117 Gabrielli GB, De Sandre G. Haematologica 1995; 80(6): 518-20 118 Chung KT, Wong TY, Wei CI et al. Crit Rev Food Sci Nutr 1998; 38(6): 421-464 119 Ganji V, Kies CV. Plant Foods Hum Nutr 1994; 46(3): 267-276 120 Herberg KW. Therapiewoche 1994; 44(12): 704-713 121 Krivoy N, Pavlotzky E, Chrubasik S et al. Planta Med 2001; 67: 209-212 122 Lynch SR. Nutr Rev 1997; 55(4): 102-110 123 Gillooly M, Bothwell TH, Charlton RW et al. Br J Nutr 1984; 51(1): 37-46

135